GL1X · GenesisL1 explorer

Research workbench

Crystal structure of the therapeutic antibody binding fragment of gevokizumab in its unbound state

Analyse Crystal structure of the therapeutic antibody binding fragment of gevokizumab… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
4G6K
Type
protein
Length
432 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Heavy chain of gevokizumab antibody binding fragment; Light chain of gevokizumab antibody…
Pockets
3 · best druggability 0.64

Structure

x-ray diffraction · 2 distinct chains · 6% helix, 51% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
HHeavy chain of gevokizumab antibody binding fragmentprotein2207% helix, 50% strand—
LLight chain of gevokizumab antibody binding fragmentprotein2126% helix, 51% strand—

Pockets

3 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
16860.640.7472empty
2740.350.7619empty
3660.290.7317empty

Interfaces

1 interface between chains.

  • H–L · 1825 Ų buried · 11 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 4 disulfide (disulfide).

Compared structures

  • 4G6K · Crystal structure of the therapeutic antibody binding fragment of gevokizumab in its… · the same entry in another collection · chain H against H, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.